Angiotensin II Stress Test (TENSINTEST): Kinetics of Renin During Treatment of Vasoplegic Shock with Angiotensin II in Connection with Hemodynamic Response to Treatment with Angiotensin II

The study investigates whether a simple laboratory measurement can help identify which patients with severe shock are most likely to respond to treatment with angiotensin II. Shock is a life-threatening condition in which organs do not receive enough blood and oxygen. Such patients are treated in an intensive care unit with medicines that increase blood pressure. One of these medicines is angiotensin II, which effectively improves blood pressure in some patients, while its effect is weaker in others.

Researchers are interested in whether the level of renin in the blood can help predict the success of treatment with angiotensin II. In the future, this could allow treatment to be more personalised and more effective for individual patients.

Purpose of the study

To determine the association between blood renin levels and the success of treatment with angiotensin II in patients with severe shock.

Study procedure

This is an observational study, which means that patients will receive standard treatment regardless of whether they participate in the study.

If the patient or their relatives decide to take part, an additional blood sample will be taken, in addition to routine tests, to determine renin levels — before the start of treatment with angiotensin II and again approximately 6 hours after treatment begins.

Participation in the study does not affect the patient’s treatment, which follows the usual intensive care procedures.

Who can take part?

Adult patients treated in an intensive care unit for shock who require treatment to raise blood pressure, including angiotensin II.

How to apply?

The possibility of participation will be explained to the patient or their relatives by physicians in the intensive care unit. Before inclusion, they will receive all necessary information and sign an informed consent form.

Participation in the study is entirely voluntary and may be withdrawn at any time without affecting further treatment.

The study does not pose any additional risk to the patient, as it only involves an additional laboratory measurement from an already collected blood sample.

By participating, patients contribute to the development of more personalised and effective treatment for critically ill patients.